Martin Münchbach is a founding partner of Pureos and has been a venture capital investor since 1999, investing in life science companies across all stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Martin’s most successful investments and board assignments include Radius Health, Molecular Partners, Optimer, Axovan and Glycart. Martin is currently a BoD member at Ypsomed Holding, Alentis Therapeutics, River Renal and Ariceum Therapeutics. Martin obtained his PhD in protein chemistry from the ETH Zurich and his MAS in Management, Technology, and Economics from ETH Zurich.
BioTech, HealthTech
Direct Professional Email Pattern
AI Outreach Agent Pitch Writer
Compose an personalized, high-converting outreach message targeting their exact investment interest...